Literature DB >> 18067118

CD133: molecule of the moment.

D Mizrak1, M Brittan, M R Alison.   

Abstract

CD133 (prominin-1) was the first in a class of novel pentaspan membrane proteins to be identified in both humans and mice, and was originally classified as a marker of primitive haematopoietic and neural stem cells. Due to the highly restricted expression of CD133 family molecules on plasma membrane protrusions of epithelial and other cell types, in association with membrane cholesterol, a role in the organization of plasma membrane topology has also recently been assigned to this family. Studies have now confirmed the utility of CD133 as a marker of haematopoietic stem cells for human allogeneic transplantation. In addition, CD133 represents a marker of tumour-initiating cells in a number of human cancers, and therefore it may be possible to develop future therapies towards targeting cancer stem cells via this marker. The development of such therapies will be aided by a clearer understanding of the molecular mechanisms and signalling pathways that regulate the behaviour of CD133-expressing cells, and new data outlining the role of Wnt, Notch, and bone morphogenetic protein (BMP) signalling in CD133(+) cancer stem cell regulation are discussed within.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18067118     DOI: 10.1002/path.2283

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  205 in total

1.  Proliferation of the ciliary epithelium with retinal neuronal and photoreceptor cell differentiation in human eyes with retinal detachment and proliferative vitreoretinopathy.

Authors:  Yvette Ducournau; Claude Boscher; Ron A Adelman; Colette Guillaubey; Didier Schmidt-Morand; Jean-François Mosnier; Didier Ducournau
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-20       Impact factor: 3.117

2.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.

Authors:  Lixia Guo; Dominic Fan; Fahao Zhang; Janet E Price; Ju-Seog Lee; Dario Marchetti; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels.

Authors:  Hisamichi Naito; Hiroyasu Kidoya; Susumu Sakimoto; Taku Wakabayashi; Nobuyuki Takakura
Journal:  EMBO J       Date:  2011-12-16       Impact factor: 11.598

Review 4.  Therapeutic application of stem cells in gastroenterology: an up-date.

Authors:  Patrizia Burra; Debora Bizzaro; Rachele Ciccocioppo; Fabio Marra; Anna Chiara Piscaglia; Laura Porretti; Antonio Gasbarrini; Francesco Paolo Russo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

5.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

6.  CD133+ CD44+ subgroups may be human small intestinal stem cells.

Authors:  Neng-Yi Hou; Kun Yang; Tie Chen; Xin-Zu Chen; Bo Zhang; Xian-Ming Mo; Jian-Kun Hu
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

7.  Proliferation of dental follicle-derived cell populations in heat-stress conditions.

Authors:  S Yao; D L Gutierrez; H He; Y Dai; D Liu; G E Wise
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 8.  EpCAM and its potential role in tumor-initiating cells.

Authors:  Sannia Imrich; Matthias Hachmeister; Olivier Gires
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

9.  CD133+ adult human retinal cells remain undifferentiated in Leukaemia Inhibitory Factor (LIF).

Authors:  Debra A Carter; Andrew D Dick; Eric J Mayer
Journal:  BMC Ophthalmol       Date:  2009-02-23       Impact factor: 2.209

Review 10.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.